Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan

Ticker(s): CALT, NVS, TVTX, KDNY

Who's the expert?

Institution: UPENN

Associate Professor of Clinical Medicine and the Clinical Director, Glomerular Diseases Program at University of Pennsylvania.
Currently manages 100 patients with IgAN, 1000 patients with CKD, and 15 patients with C3 glomerulopathy.
Research focuses on Glomerular diseases, Onconephrology, and kidney biopsy.

Interview Goal

This call will focus on the FDA approval of Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and the results from the phase 3 ALIGN study regarding Chinook's Atrasentan. This call will also compare and contrast all three medications potential for treatment of IgA Nephropathy.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.